The questions
that come up.

Summer is an independent reading guide. It does not examine people, write prescriptions, prepare medicines or sell products. A guide can explain a term, but a personal care decision belongs with a licensed provider who can review your health.

Yes. Promise Peptides offers consultations with licensed U.S. providers. Each request is reviewed by a provider, who decides whether to prescribe. Not everyone qualifies. U.S. patients only; availability varies by state and treatment.

No. A request begins a review. The provider may decide a treatment is inappropriate. If a prescription is written, a pharmacy separately decides whether it can lawfully prepare it. A service listing cannot make either decision for an individual.

A compounded medicine is prepared to meet a particular patient’s needs. Compounded medicines are not FDA-approved. The provider’s prescribing decision and the pharmacy’s responsibilities remain separate from FDA drug approval.

Yes. FDA-approved semaglutide and tirzepatide products exist. Their approval is specific to those medicines and their uses. It does not extend to compounded semaglutide or compounded tirzepatide, which are not FDA-approved.

The form matters. A small study of a skin cream cannot establish what happens with an injection containing a similarly named ingredient. GHK-Cu is one example where cosmetic use and injectable-drug questions need distinct explanations.

It describes a withdrawn request for the FDA to consider an ingredient for compounding. On the FDA’s page current as of April 22, 2026, several peptides appear in that table. Withdrawal is not FDA clearance or approval; the stated safety concerns remain.

Summer may earn money when readers become Promise patients. The disclosure appears beside the first care invitation and in the footer on every page. Summer Peptides is an independent guide and is not Promise Peptides. The relationship does not turn research findings into treatment promises.